85 results about "High dosage" patented technology

A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng / mL)) / (dose (mg)) ratio of less than 5 and / or a (mean AUC(0-24),ss (h*ng / mL)) / (Absolute Neutrophil Count (cells / mm3)) ratio on day 22 of dosing of not greater than 1.25.

The invention provides a composite collimator and a control method thereof, a radiotherapy system and a dose delivery method thereof, and relates to the technical field of radiotherapy, and the composite collimator comprises a grating and a diaphragm which are sequentially arranged in the direction of a beam center axis, the plurality of blades move to form a grating channel through which a radiation beam can pass; the diaphragm is provided with a collimation channel, and the diaphragm can move relative to a beam center axis; when the diaphragm moves to enable the collimation channel to be located at the central axis of the beam, the radiation beam forms a focusing radiation field in a target area through the grating channel and the collimation channel; and when the diaphragm moves to enable the collimation channel to deviate from the beam center axis, the radiation beam forms a conformal radiation field in the target area through the grating channel. Through switching between the conformal radiation field and the focusing radiation field, a flexible irradiation scheme is provided, so that the dose distribution effect can be improved, and the radiotherapy effect is improved.

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The pharmaceutical composition comprises gefitinib, erlotinib, afatinib, neratinib, osimertinib and the like which serve as active ingredients. The pharmaceutical composition disclosed by the invention can simultaneously contain various EGFR inhibitors as active ingredients, and the active ingredients are controlled at ultra-low dosage, so that the pharmaceutical composition not only can ensure the treatment effect, even the drug effect of the pharmaceutical composition is obviously superior to that of a high-dosage EGFR inhibitor independent administration group, but also can ensure the safety, and the pharmaceutical composition is suitable for clinical application. And after the active components are combined, a good synergistic effect is achieved, and more importantly, the occurrence of drug resistance can be remarkably reduced or even resisted. In a lung cancer cell culture experiment, the EGFR inhibitor independent administration group has a drug resistance phenomenon at the earliest 20 days, but the pharmaceutical composition group still has no drug resistance phenomenon after 160 days of administration.

A water remediation system and accompanying method includes remediation by reducing the concentration of nutrients in the water and dosing the water with metal ions. It has been found that through a combination of reducing nutrients present in the water and treating with metal ions, the requirement to treat with high chemical dosages is removed.

The invention discloses a screening and dosage determining method of a grape heat resistance inducer, and belongs to the technical field of plant stress resistance physiology and cultivation. The method comprises the following steps: soaking grape leaf wafers in inducers with different concentrations, and carrying out heat treatment under a plurality of temperature gradients; determining a chlorophyll OJIP rapid fluorescence parameter and constructing a heat resistance comprehensive index, and further calculating a normalized relative heat resistance improvement value; fitting a quantitative relation with the concentration by using a single-peak dose-effect model containing a high-dose inhibition item; statistical inference is carried out by adopting Bootstrap resampling, and a stable and effective recommended application concentration in a wide temperature range is finally determined by analyzing a common intersection or a statistical median of effective concentration intervals under multiple temperatures. The method realizes indoor rapid and quantitative screening, can realize quantitative comparison of induction intensity and dose sensitivity of different inducers under a unified evaluation system, and can be used for identifying heat resistance of grapes.

The invention discloses a hexapeptide LR6 with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and the hexapeptide LR6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide LR6 is identified from spirulina platensis proteolysis liquid and has potential interaction with Keap1, an LPS-induced RAW264.7 cell test shows that TNF-alpha, IL-1beta and IL-10 can be remarkably inhibited by treatment of low-dose (200mM) and high-dose (400mM) hexapeptide LR6, the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone, and the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone. Compared with dexamethasone, the hexapeptide LR6 has a better anti-inflammatory effect and can be used for preparing anti-inflammatory drugs.

This invention discloses an ultrafine particle soil fluidized solidifier and an intelligent pile-forming process for in-situ pre-mixed fluidized solidified soil. The solidifier comprises cement, granulated blast furnace slag powder, and other main solidifying materials, along with an organic polymeric dispersant. Through the action of a low dosage of the organic polymeric dispersant, the plastic-to-fluid transition of the cohesive solidified soil is achieved, solving the technological challenges in preparing ultrafine particle fluidized solidified materials with high dosage, low moisture content, and high strength. An innovative airtight construction process is proposed. By introducing a pressurized airflow during mixing, the gas phase space of the ultrafine particle fluidized solidified material is increased, providing space for the growth of hydration product crystals and suppressing the strength-reducing effect of the organic polymeric dispersant on the solidified soil. This achieves rapid mixing of the solidifying material and the solidified soil, significantly improving the construction efficiency of in-situ soil solidification.

A dosing mechanism for a drug delivery device is provided for selecting and dispensing user-variable doses of a medicament. The mechanism includes a housing, a piston rod, and a drive configured to rotate the piston rod and / or a movement application component directly engaged with the piston rod in a dispense rotational direction relative to the housing. A rotational end-stop mechanism terminates dose dispense and includes a first engagement element rotationally fixed to the piston rod and / or the movement application component, and a second engagement element that is constrained against rotation relative to the housing at the end of dose dispense. To improve dose accuracy, the second engagement element remains out of direct engagement with the first engagement element during dispensing, and only at the end of dose dispense directly engages the first engagement element to provide a rotational stop. A drug delivery device incorporating the dosing mechanism is also disclosed.

Aerosolization devices and procedures are described that improve air-jet dry powder inhaler (DPI) technologies and other types of inhalers, thereby optimizing aerosolization performance and expanding dosing capacity. One example device includes a variable-sized aerosolization chamber and an adjustment mechanism that allows the chamber size to be changed between activations. During use, the distance between the aerosolization chamber's air channel and the top of the powder bed remains virtually constant, even as the powder bed empties with each successive activation of the device.

An exhaust aftertreatment system comprises a pump; reagent dosing devices arranged in series with each other; and a controller. The controller comprises a dosing device diagnostic circuit configured to in a first stage measuring a first stage diagnostic indicating an amount of reagent dosed by all the reagent dosing devices, and comparing the measured first stage diagnostic with a nominal first stage diagnostic. If a deviation exceeds nominal performance then in a second stage of evaluation is triggered to identify a faulty reagent dosing device, wherein all the further reagent dosing devices are set to dose at a low quantity while simultaneously activating the first reagent dosing device to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and measuring a second stage diagnostic. The measured second stage diagnostic is compared with a nominal second stage diagnostic for determining if the first dosing device is operating correctly or faulty. In a third stage the first reagent dosing device is set to dose at a low quantity while simultaneously only one of the further reagent dosing devices is activated to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and a third stage diagnostic is measured and compared with a nominal second stage diagnostic for determining if said only one of said further reagent dosing devices is operating correctly or faulty.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and / or abscopal effects.

The utility model discloses an antibacterial softener storage and use device with an accurate proportioning structure, and aims to provide the antibacterial softener storage and use device with the accurate proportioning structure, which has the advantages that the taking convenience is improved, and the dosage precision is high. The device comprises a base; the bracket is connected with the base; the storage box is connected with the support, and the storage box is connected with a switch assembly; the material receiving assembly is connected with the base, the material receiving assembly is provided with a quantifying cup, and a quantifying plate is movably connected with the base; and the ratio control assembly is connected with the support, the ratio control assembly is provided with a material return pipe, and the material return pipe is connected with the storage box and the quantitative cup. The device has the beneficial effects that various raw materials of the antibacterial softening and moistening agent can be quickly discharged in the device through the storage device, and meanwhile, the quantity can be accurately controlled; accurate control of the proportion is realized; the structural connection and operation stability is improved, and feeding and discharging are convenient to store; the operation efficiency is improved.

The present invention describes the combination of a 5HT3-antagonist and / or NK1-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole for treating anhedonia.

A dry powder inhaler for pulmonary or nasal use, comprising at least an inhaler body (201) and a cartridge (203) with a plurality of powder compartments (205) each including one dose of a drug. The body (201) has an opening (204) shaped for receiving the cartridge (203) and the plastic body recess (215) and the detent (218) to allow a controlled advancement and turning movement of the cartridge (203) relative to the body (201) for sequentially delivering each of the plurality of unit doses filled into the cartridge compartments (205). The inhaler construction is suitable for filling the plurality of unit doses into the compartments (205) with the cartridge (203) assembled into the body (201). The invention affords a large dose inhaler of single-use and low cost that improves industrial filling and manufacturing cost for the delivery of high dosages of inhaled medicines.

The invention relates to a traditional Chinese medicine preparation, in particular to application of a compound live brain soothing capsule in preparation of a medicament for treating insomnia. The dosage of the medicine is 200 mg / kg. Experiments show that the sleep improvement effect of the compound Shuonaoshu capsule on an anesthesia reviving experiment evaluation test medicine, a high-dose group (200 mg / kg) of the compound Shuonaoshu capsule can effectively prolong sleep time, dose dependence exists, sleep quality can be moderately improved, the higher the concentration is, the more obvious the improvement effect is, and the more obvious the effect is. The invention reveals that the compound Liangjinshu capsule has a treatment effect on insomnia, and is expected to provide a certain experimental basis for the development of new drugs for insomnia.

Provided are formulations and methods to treat ultra-potent synthetic opioid overdose with high dose Naloxone formulations comprising naloxone hydrochloride or a pharmaceutically acceptable salt thereof, one or more preservatives, one or more buffering agents, a tonicity modifier, and optionally a pH modifier.

This invention discloses a universal method and composition for solving the pilling problem in cold-formulated cosmetics. Adding an effective amount of glyceryl oleate, citrate / caprylic / capric triglyceride to a cosmetic composition containing a pilling-prone cold-formulated emulsifier can significantly reduce or eliminate pilling. This substance has been discovered for the first time to have a novel anti-pilling application, effective against pilling caused by the emulsifier's own characteristics, high dosage, electrolyte interference, or the addition of large molecules, and is universally applicable to different types of cold-formulated emulsifier systems. This invention is particularly suitable for systems using electrolyte-rich natural plant extracts as the aqueous phase, fundamentally solving the pilling problem and providing a reliable solution for preparing high-feel, all-natural cold-formulated cosmetics.

Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenstrom's Macroglobulinaemia (WM), providing the rationale for investigating the combination.Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III / IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status ≥1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3 mg / m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375 mg / m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6 mg / m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375 mg / m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO 17:1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood 107:3442, 2006)Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm B. Haematological toxicity (grade≥3: anaemia 0%, neutropenia 25%, thrombocytopenia 22%) was significantly influenced by the high percentage of pts. with BM infiltration and concomitant cytopenia on entry to the trial. The most common non-haematological adverse events were fatigue (76%), nausea (56%), diarrhoea (56%), lethargy (46%). Neurotoxicity occurred in 19 pts. (46%) (10 pts. grade 1, 7 pts. grade 2, 2 pts. grade 3). Btz dose was reduced in 7 pts.; 5 doses were omitted because of neuro or haematological toxicity. In 16 pts., treatment was delayed by 1-14 days and in 24 pts. treatment was stopped prematurely. The reasons for stopping treatment were: treatment-related toxicity 11 pts., progressive disease 9 pts., patient's preference 3 pts., myocardial infarction 1 pt. One pt. was excluded having been found ineligible post randomisation. Thirty-nine pts. (21 arm A, 18 arm B) are evaluable for response so far, one having only received 1 cycle of therapy, which had to be discontinued because of excessive toxicity. 15 / 32 were in remission (CR, CRu, PR) at the completion of therapy, 7 / 7 at “mid-therapy” assessment, and 5 have yet to be evaluated. Thus the overall response rate (RR) presently is 22 / 39 (56%) (CR, CRu, PR), FL 44%, MCL 46%, WM 90%.Conclusions:The combination was active in pts. with recurrent NHL especially WM (RR 90%), despite multiple previous treatments, The weekly schedule is preferable being more convenient, as efficacious and no more toxic.Further investigation is warranted, despite not insignificant therapy compromising toxicity.

The present application relates to a kind of tetrahydroxy bile acid pharmaceutical composition and its preparation method and application.The present application provides a kind of pharmaceutical composition, it includes 100 weight parts of compound shown in formula I and 300~900 weight parts of saccharide.The present application also provides the use of the pharmaceutical composition in the preparation of drug for treating PFIC.The pharmaceutical composition of the present application can improve dose accuracy, solve the problem of poor taste of bile acid compound, easy to swallow, can improve the compliance of children drug.The pharmaceutical composition of the present application has good stability, easy to transport and store.In addition, the pharmaceutical composition of the present application realizes the stability of treatment effect under different doses, easy to accurately dose children according to body weight, while having good bioavailability, can realize good absorption and utilization in vivo.

The invention discloses an application of 3 '-sialic acid lactose in preparation of a medicine for treating Alzheimer's disease. The invention further discloses application of the 3 '-sialic acid lactose or the medicinal salt thereof in preparation of a medicine for inhibiting Tau protein aggregation, and a medicinal composition containing the 3'-sialic acid lactose. The specific sialic acid derivative can effectively block pathological aggregation of tau, and the treatment effect of the medicine on AD is remarkably improved. The 3, 3 '-sialic acid lactose is low in acute toxicity, has no genetic toxicity and reproductive toxicity after being taken for a long time at a high dosage, and has relatively good medicinal safety and relatively good medicinal prospects.

The invention discloses an FAPbBr3 crystal-based personal dose device, which comprises an electrode part and a shell part, and compared with a traditional Geiger counter, the FAPbBr3 crystal-based personal dose device can realize accurate measurement in both low-dose and high-dose environments, overcomes the problem of response saturation of the Geiger counter in high-dose environments, improves the detection capability in the low-dose environment, and improves the detection accuracy of the FAPbBr3 crystal-based personal dose device. The FAPbBr3 crystal can distinguish radiation photons with different energies, the requirement for a power supply system is reduced, meanwhile, the overall size and weight of equipment are reduced, and portability is improved. The shell part made of the aluminum alloy material provides physical protection for internal components, and the stability and the reliability in a severe environment are enhanced. When radiation particles or rays penetrate through the FAPbBr3 crystal, radiation energy is directly converted into quantifiable electric signals, then the electric signals are analyzed and recorded through the data processing part, and a more accurate, reliable and high-adaptability personal radiation protection solution is provided.

The invention belongs to the technical field of medicines, and particularly discloses an interferon exosome composition, a preparation as well as a preparation method and application of the interferon exosome composition. The composition provided by the invention comprises interferon and exosome, wherein the dosage ratio of the interferon to the exosome is (50-300): (5-30). The composition has the technical effects that 1) by limiting the dosage ratio of the interferon to the exosome, the melanoma treatment effect of the composition is remarkably improved and is superior to the treatment effect of independently using the exosome and the interferon and the treatment effect of combining the interferon with the PD-1 monoclonal antibody; and 2) the preparation prepared from the composition has good physical, chemical and biological stability, the stability of the interferon and the exosome in the preparation is greatly improved through the synergistic cooperation of various auxiliary materials, so that the same volume can bear a higher dosage of the composition, the total injection amount of a patient is effectively reduced, and the injection cost is reduced. Therefore, the pain of a patient in the injection process is remarkably relieved, and the treatment compliance of the patient is improved.

The invention relates to application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine. Rat and SH-SY5Y cell experiments are carried out, and the rat experiments prove that after intervention of different doses of GSPE, the SOD activity and the GSH content are improved, the MDA level is reduced, the antioxidant capacity of rats is recovered, autophagy is promoted, the filial generation learning and memory retention capacity is remarkably recovered, the autonomous activity capacity is recovered, anxiety behaviors are reduced, the occurrence and development processes of dental fluorosis are slowed down, and the occurrence and development of dental fluorosis are promoted. The change trends of different doses of GSPE present dose dependence, and the protection effect of a high-dose combined intervention group is most significant; in an SH-SY5Y cell experiment, the activity of the cells is improved through GSPE pretreatment, the expression quantity of cleave-caspase3 and cleaved-PARP is remarkably reduced, the autophagy process of the SH-SY5Y cells is promoted, and then the neurotoxicity caused by NaF is relieved. NaF is used as a representative, the prevention and treatment effects of GSPE on the fluorine-induced neurotoxicity are researched, and it is proved that GSPE can inhibit the NaF-induced neurotoxicity, so that the application of autophagy in preparation of drugs or health food for improving the fluorine-induced neurotoxicity from grape seed procyanidine is provided.

The invention discloses a nano drug-loading delivery system for treating methamphetamine addiction and a preparation method and a pharmaceutical preparation thereof, and belongs to the technical field of medical configuration products. According to the nano drug-loaded delivery system, exosome from HUVECs (human umbilical vein endothelial cells) engineered and modified by hypoxia pretreatment and transcription activator protein (TAT) is used as a nano carrier of cannabidiol CBD, and compared with a drug delivery mode of high-invasiveness intraventricular injection or high-dose intraperitoneal injection (40-100 mg / kg) in treatment of METH addiction at present, the nano drug-loaded delivery system has the advantages that the drug delivery efficiency is greatly improved; the nano drug-loading delivery system treats METH addiction in a nasal delivery mode, and the effective concentration of the nano drug-loading delivery system is only 2 mg / kg and is only 1 / 20 of the minimum effective concentration (40 mg / kg) of intraperitoneal injection CBD solution for treating METH addiction.

This invention relates to the field of concrete, and more particularly to a low-carbon concrete with a high dosage of industrial solid waste and its preparation method. By weight, its components include: cement: 170 parts; fly ash: 170 parts; fine aggregate: 600-800 parts; coarse aggregate: 1000 parts; water: 132 parts; polycarboxylate superplasticizer: 1 part; and modified material MIL53(Al-Fe)@SiO2: 1-5 parts. The invention prepares the MIL53(Al-Fe)@SiO2 modified material through in-situ conversion of fly ash and waste aluminum foil, and applies it to a 1:1 cement-fly ash high-dosage solid waste system. This method maintains high strength above 50 MPa and stable mechanical properties while significantly enhancing the density of the concrete, reducing chloride ion permeability from 0.34% to 0.18%, a reduction of 47.1%. This invention not only realizes the high-value utilization and low-carbon emission reduction of industrial solid waste, but also significantly improves the durability of concrete in harsh environments, and has significant environmental protection and engineering application value.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.